Red blood cell alloimmunization in pregnancy during the years 1996-2015 in Iceland: a nation-wide population study

Transfusion

Volumn 57, Issue 11, 2017, Pages 2578-2585

  Bollason, Gunnar ^a   Hjartardottir, Hulda ^b   Jonsson, Thorbjorn ^a,b   Gudmundsson, Sveinn ^b   Kjartansson, Sveinn ^b   Halldorsdottir, Anna Margret ^a,b  

^a UNIVERSITY OF ICELAND   (Iceland)

^b LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROCYTE ANTIBODY; RHESUS ANTIBODY; RHESUS D ANTIBODY; RHESUS E ANTIBODY; RHESUS M ANTIBODY; UNCLASSIFIED DRUG; ALLOANTIBODY; RHO(D) ANTIBODY;

ABORTION; ADULT; AGE; ALLOIMMUNIZATION; ANTIBODY SCREENING; APGAR SCORE; ARTICLE; BIRTH; BLOOD BANK; BODY HEIGHT; BODY WEIGHT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ERYTHROCYTE; EXCHANGE BLOOD TRANSFUSION; FEMALE; GESTATIONAL AGE; HEMOLYSIS; HUMAN; ICELAND; MAJOR CLINICAL STUDY; MULTIGRAVIDA; NEWBORN; PHOTOTHERAPY; POPULATION RESEARCH; PREGNANCY; PREVALENCE; REGISTER; STILLBIRTH; BLOOD; BLOOD GROUP INCOMPATIBILITY; IMMUNOLOGY; INFORMATION PROCESSING; PREGNANCY COMPLICATION; YOUNG ADULT;

ADULT; BLOOD GROUP INCOMPATIBILITY; DATA COLLECTION; ERYTHROCYTES; FEMALE; HEMOLYSIS; HUMANS; ICELAND; ISOANTIBODIES; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; REGISTRIES; RHO(D) IMMUNE GLOBULIN; YOUNG ADULT;

EID: 85032984502     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.14262     Document Type: Article

References (22)

1. Roberts IA. The changing face of haemolytic disease of the newborn. Early Hum Dev 2008;84:515-23.
2. Bhutani VK, Zipursky A, Blencowe H, et al. Neonatal hyperbilirubinemia and Rhesus disease of the newborn: incidence and impairment estimates for 2010 at regional and global levels. Pediatr Res 2013;74Suppl 1:86-100.
3. Weinstein L. Irregular antibodies causing hemolytic disease of the newborn: a continuing problem. Clin Obstet Gynecol 1982;25:321-32.
4. Howard H, Martlew V, McFadyen I, et al. Consequences for fetus and neonate of maternal red cell allo-immunisation. Arch Dis Child Fetal Neonatal Ed 1998;78:F62-6.
5. Nordvall M, Dziegiel M, Hegaard HK, et al. Red blood cell antibodies in pregnancy and their clinical consequences: synergistic effects of multiple specificities. Transfusion 2009;49:2070-5.
6. Koelewijn JM, Vrijkotte TG, van der Schoot CE, et al. Effect of screening for red cell antibodies, other than anti-D, to detect hemolytic disease of the fetus and newborn: a population study in the Netherlands. Transfusion 2008;48:941-52.
7. Moise KJ. Fetal anemia due to non-Rhesus-D red-cell alloimmunization. Semin Fetal Neonatal Med 2008;13:207-14.
8. Hellman-Erlingsson S. Detection of blood group antibodies in pregnancy in Iceland 1970-1984 [article in Icelandic]. Icel Med J 1986;72:321-9.
9. Qureshi H, Massey E, Kirwan D, et al. BCSH guideline for the use of anti-D immunoglobulin for the prevention of haemolytic disease of the fetus and newborn. Transfus Med 2014;24:8-20.
10. Pal M, Williams B. Prevalence of maternal red cell alloimmunisation: a population study from Queensland, Australia. Pathology 2015;47:151-5.
11. Zwingerman R, Jain V, Hannon J, Zwingerman N, Clarke G. Alloimmune red blood cell antibodies: prevalence and pathogenicity in a Canadian prenatal population. J Obstet Gynaecol Can 2015;37:784-90.
12. Gottvall T, Filbey D. Alloimmunization in pregnancy during the years 1992-2005 in the central west region of Sweden. Acta Obstet Gynecol Scand 2008;87:843-8.
13. Tiblad E, Taune Wikman A, Ajne G, et al. Targeted routine antenatal anti-D prophylaxis in the prevention of RhD immunisation—outcome of a new antenatal screening and prevention program. PLoS One 2013;8:e70984.
14. Hillyer C, Silbestein S, Ness P, Anderson K, Roback J, editors. Blood banking and transfusion medicine, basic principles and practice. 2nd ed. Philadelphia (PA): Churchill Livingstone; 2006.
15. Tovey LA, Townley A, Stevenson BJ, et al. The Yorkshire antenatal anti-D immunoglobulin trial in primigravidae. Lancet 1983;2:244-6.
16. Huchet J, Dallemagne S, Huchet C, et al. [Ante-partum administration of preventive treatment of Rh-D immunization in rhesus-negative women. Parallel evaluation of transplacental passage of fetal blood cells. Results of a multicenter study carried out in the Paris region]. J Gynecol Obstet Biol Reprod 1987;16:101-11.
17. Mayne S, Parker JH, Harden TA, et al. Rate of RhD sensitisation before and after implementation of a community based antenatal prophylaxis programme. BMJ 1997;315:1588.
18. Osaro E, Ladan MA, Zama I, Ahmed Y, Mario H. Distribution of Kell phenotype among pregnant women in Sokoto, North Western Nigeria. Pan Afr Med J 2015;21:301.
19. Koelewijn JM, Vrijkotte TG, de Haas M, et al. Risk factors for the presence of non-rhesus D red blood cell antibodies in pregnancy. BJOG 2009;116:655-64.
20. Delaney M, Wikman A, van de Watering L, et al. Blood Group Antigen Matching Influence on Gestational Outcomes (AMIGO) study. Transfusion 2017;57:525-32.
21. O'Brien KL, Kim YA, Haspel RL, et al. Provision of KEL1-negative blood to obstetric patients: a 3-year single-institution retrospective review. Transfusion 2015;55:599-604.
22. Kristinsdottir T, Kjartansson S, Hardardottir H, et al. Positive Coomb's test in newborns; causes and clinical consequences. Summary of cases diagnosed in the blood bank in the years 2005 to 2012. Icel Med J 2016;102:326-31.